TOP News

US: Moderna share loses: Moderna-CEO warns of lower vaccine effectiveness at Omikron

Washington Nationals sued by ex-employees over vaccine firing

  Washington Nationals sued by ex-employees over vaccine firing The Washington Nationals are being sued by two former employees who were fired for refusing to comply with the team’s COVID-19 vaccine mandate. Lawrence (Larry) Pardo and Brad Holman were pitching coaches in the Nats’ organization. The two refused to get the COVID-19 vaccine for religious reasons and were fired by the Nats as a result. The team instituted a mandate on Aug. 12 that went into effect on Sept. 10, leading to the firing of both men.Now the two have filed a lawsuit against the club, TMZ Sports reports.

of the Chief of the US Biotech Group Moderna, Stephane Bancel, assuming that existing Corona vaccines will be less effective against the new virus variant Omikron than against former variants.

PHILIPPE HUGUEN/AFP/Getty Images © Provided by finanzen.net Philippe Huguen / AFP / Getty Images

The Moderna chief warned in the Financial Times that it would take months before pharmaceutical companies could produce new variant-specific vaccines in masses.

The high number of omikron mutations on the spike protein and the rapid spread of the variant in South Africa signaled that the currently available vaccines would have to be modified.

It should not be assumed that the effectiveness will remain at the same level as Delta was the case, so bancel. "I think she will sink considerably," he added. "I do not know how much, because we have to wait for data. But all scientists I've talked to say: 'That does not look good.'"

Currently, the Nasdaq-noted Moderna share is temporarily at 7, 44 percent back to $ 341.1 US dollars. The shares of Biiontech bend on Tuesday: they temporarily lose 6.78 percent to $ 337.93. Frankfurt (Dow Jones) / (DPA-AFX)

Omikron Despite Booster: Seven Germans infect in South Africa .
Preiser warned at the same time: "Of course, you can not misunderstand that the vaccine does not help. On the contrary, this only shows that the best possible vaccine obviously is not enough to prevent infection - which we have already known. "The study of Preiser and Colleagues from Thursday is not yet published in a journal. © Provided by Berliner Zeitung None of the seven Germans aged 25 to 39 had to fight with a serious course of infection.

See also